WallStSmart

Bluejay Diagnostics Inc (BJDX)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BSX leads profitability with a 17.5% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 72/100 (B).

BJDX

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -7.47

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BJDX.

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BJDX2 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

Areas to Watch

BJDX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$928,4503/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BJDX

The strongest argument for BJDX centers on Price/Book, Debt/Equity.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bear Case : BJDX

The primary concerns for BJDX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Key Dynamics to Monitor

BJDX profiles as a value stock while BSX is a mature play — different risk/reward profiles.

BJDX carries more volatility with a beta of 0.91 — expect wider price swings.

BSX is growing revenue faster at 7.5% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 26/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bluejay Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bluejay Diagnostics Inc. is an innovative medical technology company focused on revolutionizing patient care through its cutting-edge diagnostic solutions, with a strong emphasis on early disease detection. Utilizing a proprietary platform that combines advanced artificial intelligence with point-of-care testing, Bluejay enhances diagnostic accuracy and accelerates result delivery, thereby equipping healthcare providers with critical insights in real-time. The company is strategically poised to confront notable healthcare challenges and fulfill the growing demand for reliable and advanced diagnostic tools, leveraging its robust commitment to research and development in a rapidly evolving medical landscape.

Visit Website →

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?